Literature DB >> 34012034

Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".

Ion Cristóbal1,2, Andrea Santos3,4, Jaime Rubio3,5, Federico Rojo6, Jesús García-Foncillas7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34012034      PMCID： PMC8367958          DOI： 10.1038/s41416-021-01433-7

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  10 in total

1.  Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma.

Authors:  Angel Chao; Chia-Lung Tsai; Pei-Chi Wei; Swei Hsueh; An-Shine Chao; Chin-Jung Wang; Chi-Neu Tsai; Yun-Shien Lee; Tzu-Hao Wang; Chyong-Huey Lai
Journal:  Cancer Lett       Date:  2009-11-08       Impact factor: 8.679

2.  Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion.

Authors:  Qingli Shen; Vito R Cicinnati; Xiaoyong Zhang; Speranta Iacob; Frank Weber; Georgios C Sotiropoulos; Arnold Radtke; Mengji Lu; Andreas Paul; Guido Gerken; Susanne Beckebaum
Journal:  Mol Cancer       Date:  2010-08-27       Impact factor: 27.401

3.  PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.

Authors:  Paula González-Alonso; Ion Cristóbal; Rebeca Manso; Juan Madoz-Gúrpide; Jesús García-Foncillas; Federico Rojo
Journal:  Tumour Biol       Date:  2015-08-04

4.  miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.

Authors:  Zhigang Zhao; Shankun Zhao; Lianmin Luo; Qian Xiang; Zhiguo Zhu; Jiamin Wang; Yangzhou Liu; Jintai Luo
Journal:  Br J Cancer       Date:  2020-11-26       Impact factor: 7.640

5.  Downregulation of miR-199a-5p promotes prostate adeno-carcinoma progression through loss of its inhibition of HIF-1α.

Authors:  Jinjing Zhong; Rui Huang; Zhengzheng Su; Mengni Zhang; Miao Xu; Jing Gong; Ni Chen; Hao Zeng; Xueqin Chen; Qiao Zhou
Journal:  Oncotarget       Date:  2017-05-31

6.  Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer.

Authors:  Ion Cristóbal; Blanca Torrejón; Jaime Rubio; Andrea Santos; Manuel Pedregal; Cristina Caramés; Sandra Zazo; Melani Luque; Marta Sanz-Alvarez; Juan Madoz-Gúrpide; Federico Rojo; Jesús García-Foncillas
Journal:  J Clin Med       Date:  2019-03-12       Impact factor: 4.241

7.  Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.

Authors:  Chun-Yu Liu; Tzu-Ting Huang; Yi-Ting Chen; Ji-Lin Chen; Pei-Yi Chu; Chun-Teng Huang; Wan-Lun Wang; Ka-Yi Lau; Ming-Shen Dai; Chung-Wai Shiau; Ling-Ming Tseng
Journal:  EBioMedicine       Date:  2019-01-14       Impact factor: 8.143

8.  Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.

Authors:  Xiaoyong Hu; Consuelo Garcia; Ladan Fazli; Martin Gleave; Michael P Vitek; Marilyn Jansen; Dale Christensen; David J Mulholland
Journal:  Sci Rep       Date:  2015-11-13       Impact factor: 4.379

9.  SET contributes to the epithelial-mesenchymal transition of pancreatic cancer.

Authors:  Hardik R Mody; Sau Wai Hung; Kineta Naidu; Haesung Lee; Caitlin A Gilbert; Toan Thanh Hoang; Rakesh K Pathak; Radhika Manoharan; Shanmugam Muruganandan; Rajgopal Govindarajan
Journal:  Oncotarget       Date:  2017-07-07

10.  Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.

Authors:  Ion Cristóbal; Cristina Caramés; Raúl Rincón; Rebeca Manso; Juan Madoz-Gúrpide; Blanca Torrejón; Paula González-Alonso; Federico Rojo; Jesús García-Foncillas
Journal:  Oncotarget       Date:  2017-06-20
  10 in total
  1 in total

1.  Reply to Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition".

Authors:  Zhigang Zhao; Shankun Zhao
Journal:  Br J Cancer       Date:  2021-07-20       Impact factor: 9.075
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.